Browsing Tag
biotech stocks
14 posts
Can GLP‑1 drugs tackle Alzheimer’s? Novo Nordisk’s setback raises doubts
Can Novo Nordisk challenge Eli Lilly’s GLP-1 lead with Alzheimer’s data? A crucial trial may redefine the future of semaglutide and reshape investor sentiment.
Belite Bio wins UK MHRA nod to file conditional marketing application for tinlarebant in Stargardt disease
Find out how Belite Bio gained UK MHRA backing to file a conditional marketing application for tinlarebant, advancing the first potential therapy for Stargardt disease.
First patient dosed in Adagene’s Phase 2 study of Muzastotug (ADG126) with KEYTRUDA for microsatellite stable colorectal cancer
Find out how Adagene’s Muzastotug and KEYTRUDA combination could redefine immunotherapy for microsatellite stable colorectal cancer.
Why these five U.S. stocks soared over 20% on October 30: Guardant Health to Metsera
Find out how Guardant Health, FormFactor, Viavi Solutions, Globalstar, and Metsera triggered massive market moves on October 30, 2025.
Radiopharm Theranostics (ASX: RAD) crashes 21.6% despite A$40m capital raise and clinical milestones
Radiopharm Theranostics shares fall 21.6% after A$40m raise, but strong clinical updates and Lantheus support point to long-term upside. Read the full investor breakdown.
GRAIL stock surges 14% after $110m Samsung deal to expand Galleri test in Asia
GRAIL stock jumps 14% after Samsung's $110M investment and Asia commercialization deal for its Galleri cancer test. Learn how investors are reacting.
Crinetics Pharmaceuticals shares soar after FDA clears Palsonify, the first oral acromegaly treatment
Crinetics shares surged after FDA approval of Palsonify, the first oral acromegaly therapy. Learn how this launch reshapes patient care and investor sentiment.
Tonix Pharmaceuticals (NASDAQ: TNXP) surges 9.5% as fibromyalgia data and vaccine platform boost investor confidence
Tonix Pharmaceuticals stock surged 9.5% after new fibromyalgia and mpox vaccine data. Find out what’s driving investor optimism and what comes next.
Rhythm Pharmaceuticals (RYTM) surges 35% after announcing Phase 2 trial data reveal for oral MC4R agonist bivamelagon
Find out why Rhythm Pharmaceuticals stock surged over 35% and what the upcoming bivamelagon trial results mean for its rare disease pipeline.
X4 Pharmaceuticals (NASDAQ: XFOR) gets FDA fast track for mavorixafor in chronic neutropenia
X4 Pharmaceuticals (XFOR) secures FDA Fast Track for mavorixafor in chronic neutropenia, targeting trial completion in 2025 and results in 2026.